Median value (range) | AAV (n=12) | SLE (n=9) | ||
---|---|---|---|---|
pre RTX | post RTX | pre RTX | post RTX | |
CD27–IgD+CD38++ transitional B cells/μl | 0.9 (0.03–84) | 0 (0–0.04)**** | 0.8 (0.3–11) | 0.05 (0–32)* |
CD27–IgD+ naïve B cells/μl | 35 (2.4–153) | 0 (0–0.01)**** | 13 (0.6–324) | 0 (0–0.4)*** |
CD27++CD38++PB/PC/μl | 1.4 (0.05–14) | 0.05 (0–0.8)** | 5 (0.7–10) | 1 (0.02–12)ns |
CD27+ memory B cells/μl | 6 (0.8–60) | 0.06 (0–1)**** | 15 (3–112) | 1.3 (0–5)*** |
CD19+ B cells/μl | 61 (7–255) | 0.2 (0–1.8)**** | 68 (14–365) | 2.3 (0.2–51)*** |
AAV, ANCA-associated vasculitis; SLE, systemic lupus erythematosus; RTX, rituximab; PB, plasmablasts; PC, plasma cells; ns = not significant. Statistical significance determined by Mann Whitney t test is indicated (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).